LIGHT-CHAIN CARDIAC AMYLOIDOSIS
Clinical trials for LIGHT-CHAIN CARDIAC AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new LIGHT-CHAIN CARDIAC AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for LIGHT-CHAIN CARDIAC AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Triple-Drug combo tame a rare heart disease?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of selinexor, daratumumab, and dexamethasone (called XDd) can help people with advanced light-chain cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if the regimen can achiev…
Matched conditions: LIGHT-CHAIN CARDIAC AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cell therapy trial targets Hard-to-Treat heart amyloidosis
Disease control Not yet recruitingThis study tests a new treatment for people with a rare disease called light-chain cardiac amyloidosis that has come back or not responded to other treatments. The treatment uses specially engineered immune cells (CAR-NK cells) from donated umbilical cord blood to target and atta…
Matched conditions: LIGHT-CHAIN CARDIAC AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC